Brexit: How To Avoid UK Regulatory Divergence And Medicines Access Delays
Health policy consultant Nick Fahy says that a much wider debate is needed on how to address the effects of Brexit in terms of possible regulatory divergence and reduced access to medicines in the UK, and suggests two ways forward.
You may also be interested in...
The UK regulator wants to be a “catalyst for change” in reducing regulatory burdens, saying that better regulation based on science is in everyone’s interest.
Preparing for the assessment and post-approval monitoring of COVID-19 vaccines is taking up a lot of resources at the EMA, which has called on the European Commission to provide more support for such activities. The agency has also confirmed that no data have yet been submitted for its planned rolling reviews of potential vaccines.
The UK medicines regulator has a “unique opportunity” to evaluate the systems it operates and to “do things differently", according to its long-term interim head, June Raine.